Humasis Approves Establishment of U.S. Corporation... "Full-Scale Promotion of Localization Business"

[Asia Economy Reporter Lee Gwan-joo] Humasis announced on the 26th that its board of directors has approved the establishment of a local subsidiary in the United States and will begin the formal establishment process.

Humasis plans to invest a total of 2 million USD (approximately 2.6 billion KRW) with the goal of completing the subsidiary establishment next month. Through this, it is expected to promote localization business in North America, the world's largest market in the diagnostic field. Based on the approval of personal use certification for the COVID-19 self-test kit in Canada on the 22nd of last month, Humasis plans to focus on expanding supply volume.

Additionally, through the U.S. subsidiary, Humasis intends to proceed with the U.S. Food and Drug Administration (FDA) approval process and establish a foothold for launching new products in the North American market in preparation for the post-COVID-19 era. Currently, Humasis is recognized for its technology, supplying diagnostic products to about 70 countries.

A Humasis official stated, “By establishing a U.S. subsidiary, we plan to carry out more active localization business, such as strengthening contact points with local customers,” and added, “We also plan to actively pursue additional FDA approvals for key products, which is expected to enhance brand awareness in the largest market, the United States.”

This content was produced with the assistance of AI translation services.